Since their invention in the early 2000s, tyrosine kinase inhibitors (TKIs) have gained
prominence as the most effective pathway-directed anti-cancer agents. TKIs have shown …

Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders
characterized by activated Janus kinase (JAK)–signal transducer and activator of …

Background Janus kinase (JAK) inhibitors approved for myelofibrosis provide spleen and
symptom improvements but do not meaningfully improve anaemia. Momelotinib, a first-in …

PURPOSE Standard therapy for myelofibrosis comprises Janus kinase inhibitors (JAKis), yet
spleen response rates of 30%-40%, high discontinuation rates, and a lack of disease …

In patients with cytopenic myelofibrosis, treatment with the JAK2/IRAK1 inhibitor pacritinib
was associated with anemia benefit in the phase 3 PERSIST-2 study. The impact of …

Janus kinase (JAK) 2 inhibitors are now part of the therapeutic armamentarium for primary
and secondary myelofibrosis (MF). Patients with MF endure shortened survival and poor …

The Janus kinase (JAK) signal transducer and activator of transcription (JAK-STAT) pathway
is an evolutionarily conserved mechanism of transmembrane signal transduction that …

Myelofibrosis (MF) is a chronic myeloproliferative neoplasm characterized by bone marrow
fibrosis, anemia, extramedullary hematopoiesis, and splenomegaly. Patients with MF are at …

Signal transducer and activator of transcription (STAT) proteins compose a family of
transcription factors critical for cancer stem cells (CSCs), and they are involved in …

Background The MOMENTUM study met all key endpoints at week 24, demonstrating
symptom, spleen, and anaemia benefits with momelotinib versus danazol in patients with …